

Charity Registration No. 286736

Company Registration No. 01704872 (England and Wales)

SCLERODERMA SOCIETY (THE)
(LIMITED BY GUARANTEE AND NOT HAVING A SHARE CAPITAL)
TRUSTEES' REPORT AND UNAUDITED ACCOUNTS
FOR THE YEAR ENDED 31 MARCH 2016

SCLERODERMA SOCIETY (THE)

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Ms S E Hoare
Ms H Rozga
Mr C J Coombe
Professor D G I Scott
Mr K B Hicks
Professor J D Pearson

Charity number

286736

Company number

01704872

Registered office

Bride House
18-20 Bride Lane
London
EC4Y 8EE

Independent examiner

Robert Barry Perez
Silver Levene (UK) Limited
Chartered Certified Accountants
37 Warren Street
London
W1T 6AD

SCLERODERMA SOCIETY (THE)

CONTENTS

	Page
TRUSTEES' REPORT	1
INDEPENDENT EXAMINER'S REPORT	7
STATEMENT OF FINANCIAL ACTIVITIES	8
BALANCE SHEET	9
NOTES TO THE ACCOUNTS	10 - 18

SCLERODERMA SOCIETY (THE)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2016

The trustees present their report and accounts for the year ended 31 March 2016.

The accounts have been prepared in accordance with the accounting policies set out in note 1 and comply with the Charities Act 2011, the Companies Act 2006 and the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard for Smaller Entities.

Structure, governance and management

The Scleroderma Society (the Society) is a charitable company limited by guarantee, incorporated on 8 March 1983 and registered as a charity on 7 April 1983. The company was established under a Memorandum of Association, which established the objects and powers of the charitable company and is governed by the Articles of Association.

The trustees, who are also the directors for the purpose of company law, and who served during the year were:

Ms S E Hoare

Ms H Rozga

Mrs G J Kadish

(Appointed 31 October 2015 and resigned 4 September 2016)

Mr C J Coombe

(Appointed 11 December 2015)

Professor D G I Scott

(Appointed 31 October 2015)

Mr K B Hicks

(Appointed 31 October 2015)

Professor J D Pearson

(Appointed 31 October 2015)

The trustees may appoint any member to position of trustee at any point during the year, and duly appointed trustees stand for re-election by the members at the following AGM.

The trustees have no beneficial interest in the company. The trustees are directors of the company and guarantee to contribute £1 in the event of a winding up.

The trustees undertake strategic management of the charity, supported by three salaried staff members, until the point of merger, in the roles of Charity Development Manager, Policy and Research Advisor, Finance and Office Administrator.

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks. The trustees attended a conference to keep abreast of best- practice governance in the voluntary sector.

During the period of trade the principal risks faced by the charity were loss of income if the charity's stakeholders were not to support the merger of the Society with the Raynaud's & Scleroderma Association (RSA), and fundraising income were to fall as a result. To mitigate against this risk, a comprehensive communications and engagement strategy was implemented to keep stakeholders supportive and engaged with the charity.

The trustees also engaged independent experts to conduct a full due diligence on the state of both the Society and the RSA to ensure full visibility of the financial and legal health of both organisations before proceeding to merger.

SCLERODERMA SOCIETY (THE)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2016

Merger

The trustees of the Society and the RSA continued to hold regular joint meetings during the year to discuss the most appropriate future for the beneficiaries of both organisations, with view to a potential merger of the two.

During 2014-2015, the trustee boards had jointly commissioned an independent party to conduct a due diligence process to review the legal, commercial and financial health of both organisations to determine the suitability of a merger. The report was positive and during 2015-2016, the trustees decided to proceed with a formal merger of both charities.

The trustees sought independent legal advice on the most appropriate means of conducting a merger. Charity law specialist firm Russell Cooke recommended that the trustees apply to the Charity Commission to establish a new charity in the form of a CIO, and to transfer the assets of both The Society and RSA into the new CIO.

The Charity Commission approved the formation of the new CIO named Scleroderma & Raynaud's UK (SRUK) in May 2015. The trustees appointed Sue Farrington as CEO, and the first employee, in July 2015. The CEO then proceeded to manage the transfer of staff and assets from the Scleroderma Society and RSA into SRUK, and to prepare for the launch of SRUK.

Both trustee boards joined to form the SRUK trustee board.

The legal process required all trustees of the newly formed charity to be appointed trustees and directors of the Society, so the trustees of the RSA were appointed trustees of the Society on 31 October 2015. Christopher Coombe was also appointed as Trustee of the new charity on 3 February 2016 and accordingly was appointed as Trustee and Director of the Society.

The formal merger took place on 31 October 2015. From that date SRUK began to integrate operations from the two legacy charities. All front line services continued as normal and were not affected during this time. SRUK used the existing brands of the Scleroderma Society and RSA until 31 March 2016 when the new SRUK brand was launched.

Since SRUK launched both the Society and RSA continue to exist as dormant inactive charities. This is to ensure that any funds that may be donated to either organisation can be received and then passed on to SRUK so we can continue our vital work. In order for the Society to become a subsidiary dormant charity of SRUK, the trustees were required to amend the Society's Articles of Association with the following resolution:

"That the Memorandum and Articles of Association of the Company be deleted in their entirety and replaced by the Articles of Association in the form attached in substitution for all former Articles of Association. For the avoidance of doubt, clauses 1 to 5 of the Memorandum of Association are being replaced by provisions within the Articles of Association."

The trustees therefore held an Extraordinary General Meeting on 2 November 2015 and the proposed resolution was passed unanimously.

The trustees were satisfied that the Society was delivering its aims and fulfilled its charitable objects for the benefit of the public and that the Society was in appropriate financial health to proceed to merging during the 2015-2016 financial year.

SCLERODERMA SOCIETY (THE)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2016

Objectives and activities

The Society's objects are to help people living with scleroderma, to promote and disseminate the results of research into its causes and treatment and to advance the education of the public about such conditions.

The trustees have fulfilled their duty to bear due regard to the Charity Commission's public benefit guidance in their decision-making activities. The charity acts in the following ways to achieve its objects:

- Funds grants to suitable research applicants conducting clinical and scientific research into the cause and potential therapies for treating scleroderma;
- Supports people affected by scleroderma by the provision of extensive up-to-date, reliable information on the disease, its treatments, and ways of managing the condition;
- Assists those in need of financial assistance with small grants to cover costs associated with the condition that they cannot afford;
- Manages a support network online, on telephone, and through local groups; Undertakes awareness campaigns to educate the public and healthcare professionals;
- Advocates the cause of those affected by scleroderma by engaging with the healthcare organisations and professionals, scientists, and policy makers;
- Undertakes fundraising activities to enable the Charity to operate and deliver these activities.

Achievements and performance

The charity maintained the following values:

Patient-focused- Scleroderma patients are at the heart of our working. We strive to be the voice of diagnosed individuals, to enable them to manage their diagnosis through collaboration with the health and research community and to challenge decision-makers on behalf of patients.

Informative -We strive to provide comprehensive, unbiased and up-to-date information. To demonstrate this commitment, we are accredited members of the Information Standards.

Passion - Our staff and volunteers are dedicated to improving the lives of people affected by scleroderma.

Transparent - We are dedicated to being open and honest in all of our work. To demonstrate this commitment, we are members of the FRSB (Fundraising Standards Board).

Accessible - We aim to be a charity available to all and carefully consider our working to enable this.

Research

The Society remains a member of the FRSB (Fundraising Standards Board) demonstrating the charity's commitment to fundraising best practice. The Society invested £87,015 in research during the year; fundraising activities conducted by supporters, members, volunteers and staff played a valuable contribution in enabling the Society to make this expenditure. Research grants were awarded to:

- University College London for three research projects - Vascular Disease in Scleroderma: Key Pathways in Pulmonary Arterial Hypertension (£38,500); the role of B-Lymphocytes in Scleroderma (£15,000) and Using Genetics and Gene Expression to Understand Diversity in Scleroderma (£25,000). In addition a grant was awarded to UCL for investigating the role of the ATP-P2X7R pathway in systemic sclerosis.

SCLERODERMA SOCIETY (THE)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2016

Awareness

Building on the work of recent years, in 2015-2016, the Society conducted the following activities to raise awareness:

The Society attended a range of clinician-focused conferences to disseminate information and support practitioners in managing and treating patients with scleroderma. The two most notable conferences attended were the British Society of Rheumatology and Nursing in Practice.

The Society was instrumental in developing and delivering a global awareness campaign for World Scleroderma Day 2015. The campaign slogan was 'unveiling scleroderma' and organisations across the globe were asked to support this through sharing the official video, organising events and encouraging members to go onto the WSD website and make their voice heard by signing a petition. This petition focused on three key areas, which were discussed during our European Parliament seminar:

1. Why early diagnosis is vital
2. The need for investment in research
3. Why equity of care across Europe is crucial

Since our European Parliament Seminar we have been working with a range of stakeholders, engaging in discussions around diagnosis times.

To support this work we conducted a survey entitled 'Your Diagnosis' in which we identified 51.25% of respondents waited over two years to receive a diagnosis of scleroderma.

SCLERODERMA SOCIETY (THE)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2016

Support

The Society has an established history of excellent support material. During this year, the Society continued to provide excellent information and support services including an informative website, volunteer-led helpline offering support 365 days a year and educational events.

During 2015 the Society received Information Standard accreditation demonstrating our commitment to driving up the quality of health and care information that is available to the public. All of our printed publications went through the process and displayed the Information Standard mark showcasing that our information clear, accurate, evidence-based, up-to-date and easy to use.

To keep our community informed we released four printed newsletters, which provided ideas on how to self-manage their condition, personal stories, research news and an overview of the work that the charity was undertaking. We know that for many this quarterly newsletter provides a lifeline of support.

Alongside this we began supporting our community on a national level through engaging with policy consultations to create change for our community. The Society inputted into two policy consultations for investment in to specialised services and incorporating Sildenafil and Bosentan into the treatment pathway for scleroderma patients. We are delighted that this pathway is now a formal clinical guideline.

Finally through the year we organised support events including a hands on workshop for skin care and our annual conference, the largest event throughout the year bringing together the scleroderma community. The following is just some of the feedback we received:

"As a newly diagnosed individual I have found today to be invaluable in terms of both clinical development and how others are coping with the condition"

"I really enjoyed learning about my mum's disease and how it affects her daily life."

The Society received a donation from The Brian Norris Charity Appeal of the value £25,928 to fund an ultra sound machine for the PITU unit at the Royal Free hospital, providing patients with a choice of treatment and a Family Day to inform, educate and empower families to better manage their child's condition.

In November we merged our newsletter with that of the RSA to reduce costs in advance of the launch of the new SRUK branded newsletter on the 31 March 2016

SCLERODERMA SOCIETY (THE)

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2016

Financial review

It should be noted that this report covers the twelve-month period April 2015 - March 2016. However, all assets were transferred from the Society to the new charity SRUK after the merger on the 31st October. The figures quoted for the previous financial year (given in brackets) were for the full twelve month period to 31 March 2015.

Income and other gains for the year were £143,934 (2015: £147,071) and total expenses were £218,164 (2015: £220,754). This produced a net deficit for the year of £74,230 (2015: £73,683).

At 31 October 2015, total reserves amounted to £459,704 (2015: £533,934) of which £10,546 (2015: £74,387) were restricted. Unrestricted funds amounted to £449,158 (2015: £459,547). These were transferred to SRUK on 1 November 2015.

On behalf of the board of trustees



.....
Ms S E Hoare
Trustee

Dated: 21/01/2017

SCLERODERMA SOCIETY (THE)

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SCLERODERMA SOCIETY (THE)

I report on the accounts of the Society for the year ended 31 March 2016, which are set out on pages 8 to 18.

Respective responsibilities of trustees and examiner

The trustees, who are also the directors of Scleroderma Society (The) for the purposes of company law, are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011, the 2011 Act, and that an independent examination is needed.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- (i) examine the accounts under section 145 of the 2011 Act;
- (ii) to follow the procedures laid down in the general directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- (iii) to state whether particular matters have come to my attention.


Basis of independent examiner's report

My examination was carried out in accordance with the general directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- a) which gives me reasonable cause to believe that in any material respect the requirements:
 - (i) to keep accounting records in accordance with section 386 of the Companies Act 2006; and
 - (ii) to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities;have not been met; or
- b) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Robert Barry Perez
Silver Levene (UK) Limited
Chartered Certified Accountants
37 Warren Street London
W1T 6AD
Dated: 24 January 2017

SCLERODERMA SOCIETY (THE)

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2016

	Notes	Unrestricted funds £	Designated funds £	Restricted funds £	Total 2016 £	Total 2015 £
Income from						
Donations, Legacies & membership fees	4	45,548	-	25,929	71,477	100,115
Other trading activities	2	1,981	-	-	1,981	839
Charitable activities	4	57,873	-	11,747	69,620	44,026
Investments	3	856	-	-	856	2,091
Total income		106,258	-	37,676	143,934	147,071
Expenditure on:						
Raising funds		27,099	3,993	-	31,092	45,848
Charitable activities						
Promotion of research into scleroderma		12,842	-	74,173	87,015	66,074
Information and support		24,219	7,675	18,374	50,268	70,741
Campaign and awareness		19,117	21,702	8,970	49,789	38,091
Total charitable expenditure		56,178	29,377	101,517	187,072	174,906
Total expenditure		83,277	33,370	101,517	218,164	220,754
Net income / (expenditure)		22,981	(33,370)	(63,841)	(74,230)	(73,683)
Gross transfers between funds		126,630	(126,630)	-	-	-
Net movements in funds		149,611	(160,000)	(63,841)	(74,230)	(73,683)
Fund balance brought forward		299,547	160,000	74,387	533,934	607,617
Transfer to Scleroderma & Raynaud's UK		(449,158)	-	(10,546)	(459,704)	-
Fund balances at 31 March 2016		-	-	-	-	533,934

All activities relate to discontinued operations following the transfer of the charitable activities, undertaking, assets and liabilities to Scleroderma & Raynaud's UK on 1 November 2015

SCLERODERMA SOCIETY (THE)

BALANCE SHEET

AS AT 31 MARCH 2016

Company Registration No. 01704872

	Notes	2016 £	2015 £
Fixed assets			
Tangible assets	10	-	1,159
Current assets			
Debtors	11	- 8,886	
Cash on deposit and in hand		- 531,753	
		- 540,639	
Creditors: amounts falling due within one year	12	- (7,864)	
Net current assets		-	532,775
Net assets		-	533,934
Income funds			
Restricted funds	13	-	74,387
Unrestricted funds			
Designated funds	14	-	160,000
Other charitable funds		- 299,547	
		- 533,934	

The assets and liabilities were transferred to Scleroderma & Raynaud's UK on 1 November 2015.

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2016. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these accounts.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Companies Act 2006 and for preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

These accounts have been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

The accounts were approved by the Board on 21/01/2017


.....
Ms S E Hoare
Trustee

SCLERODERMA SOCIETY (THE)

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31 MARCH 2016

1 Accounting policies

1.1 Basis of preparation

The accounts have been prepared under the historical cost convention unless otherwise stated in the relevant accounting policy note.

The accounts have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard for Smaller Entities, the Financial Reporting Standard for Smaller Entities (effective January 2015) and the Companies Act 2006.

On 7 October 2015, a deed of transfer was signed between the charity and Scleroderma & Raynaud's UK ("SRUK"), a charitable incorporated organisation in which the charity will transfer its assets and undertaking to SRUK to carry on its charitable activities with effect from 1 November 2015. As a result of this, the charity ceased its activities on 31 October 2015.

1.2 Income

All income is included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy.

Donations, legacies, membership fees and other forms of voluntary income are recognised as incoming resources when there is a probability of receipt, except insofar as they are incapable of financial measurement.

Investment income is included when receivable.

1.3 Expenditure

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Cost of generating funds comprises the costs associated with attracting voluntary income.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries.

Support and governance costs are those functions that assist the work of the charity but do not directly undertake charitable activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities.

1.4 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Fixtures, fittings & equipment	3 - 5 years on cost
--------------------------------	---------------------

SCLERODERMA SOCIETY (THE)
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016

2 Other trading activities

	2016	2015
	£	£
Activities for generating funds	1,981	839
Costs of goods sold and other costs	(1,029)	(3,204)
Net activities for generating funds	<u>952</u>	<u>(2,365)</u>

3 Investment income

	2016	2015
	£	£
Interest receivable	<u>856</u>	<u>2,091</u>

SCLERODERMA SOCIETY (THE)
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016

4 Income from donations, legacies, membership fees and charitable activities

	2016	2015
	£	£
Donations, legacies and membership fees	71,477	100,115
Income from charitable activities	69,620	44,026
	<u>141,097</u>	<u>144,141</u>
Analysed as follows:		
Events and sponsored activities	58,068	44,026
Donations	51,618	59,606
Legacies	7,600	25,000
Membership fees	2,820	3,620
Gift aid	9,439	11,889
	<u>129,545</u>	<u>144,141</u>
Grants receivable from institutions:		
FESCA	10,052	-
Actelion	1,500	-
	<u>11,552</u>	<u>-</u>
Total	<u>141,097</u>	<u>144,141</u>

SCLERODERMA SOCIETY (THE)

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2016

5 Total costs

	Staff costs £	Other costs £	Grant funding £	Total 2016 £	Total 2015 £
Expenditure on raising funds					
Expenditure on generating donations, legacies and membership fees	-	14,821	-	14,821	22,926
Expenditure on goods sold and other costs	-	1,029	-	1,029	3,204
Fundraising staff costs	15,242	-	-	15,242	19,718
Total	15,242	15,850	-	31,092	45,848
Charitable activities					
<i><u>Promotion of research into scleroderma</u></i>					
Grant funding of activities	-	-	87,015	87,015	66,074
Total	-	-	87,015	87,015	66,074
<i><u>Information and support</u></i>					
Activities undertaken directly	17,001	7,763	15,518	40,282	54,580
Support costs	-	5,238	-	5,238	4,032
Governance Costs	1,439	3,309	-	4,748	12,129
Total	18,440	16,310	15,518	50,268	70,741
<i><u>Campaign and awareness</u></i>					
Activities undertaken directly	15,381	9,760	-	25,141	27,965
Support costs	-	15,152	-	15,152	4,062
Governance Costs	2,879	6,617	-	9,496	6,064
Total	18,260	31,529	-	49,789	38,091
Total Charitable activities	36,700	47,839	102,533	187,072	174,906
Total Expenditure	51,942	63,689	102,533	218,164	220,754

SCLERODERMA SOCIETY (THE)
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016

6 Total expenditure	Fundraising costs	Research grants	Campaign & awareness	Information & support	Total
	£	£	£	£	£
Grants awarded	-	87,015	-	-	87,015
Assistance grants	-	-	-	49	49
Information and literature	-	-	-	1,490	1,490
Helpline costs	-	-	-	378	378
Conferences	-	-	1,087	148	1,235
Fundraising costs	4,029	-	-	-	4,029
Event entry	42	-	7,803	2,972	10,817
Donation website fees	3,349	-	-	-	3,349
Cost of goods sold	800	-	-	-	800
Salaries and wages	15,241	-	15,380	17,001	47,622
Media relations	1,580	-	630	630	2,840
Rent and utilities	2,080	-	1,510	1,577	5,167
Office costs	638	-	621	938	2,197
IT and website costs	1,373	-	1,144	1,144	3,661
Administration costs	1,315	-	1,119	1,349	3,783
Insurance	-	-	-	-	-
Medical equipment	-	-	-	15,518	15,518
Subscriptions	195	-	241	1,877	2,313
Professional fees	450	-	10,758	450	11,658
Governance	-	-	9,496	4,747	14,243
	31,092	87,015	49,789	50,268	218,164

SCLERODERMA SOCIETY (THE)
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016

7 Grants payable

	2016 £	2015 £
Grants to institutions:		
Medical research	87,015	66,074
Equipment	15,518	-
	102,533	66,074

All grants awarded during the year had been paid. No outstanding balance was transferred.

8 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year, and total expenses to reimburse trustees was £817 (2015: £1,946) for travelling and other expenses.

9 Employees

Number of employees

The average number of employees during the year, while the charity was active was:

	2016 Number	2015 Number
	3	3
Employment costs	2016 £	2015 £
Wages and salaries	50,704	62,582
Social security costs	1,238	2,394
	51,942	65,246

SCLERODERMA SOCIETY (THE)
NOTES TO THE ACCOUNTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2016

10 Tangible fixed assets

	Fixtures, fittings and equipment £
Cost	
At 1 April 2015	-
Additions	1,159
Transfers	(1,159)
	<hr/>
At 31 March 2016	-
	<hr/>
Depreciation	
At 1 April 2015 and at 31 March 2016	-
	<hr/>
Net Book Value	
At 31 March 2016	-
At 31 March 2015	1,159
	<hr/>

11 Debtors

	2016 £	2015 £
Donations and gift aid receivable	-	2,949
Staff travel and advances	-	2,736
Prepayments	-	3,201
	<hr/>	<hr/>
	-	8,886
	<hr/>	<hr/>

12 Creditors: amounts falling due within one year

	2016 £	2015 £
Taxes and social security costs	-	1,500
Accruals	-	6,364
	<hr/>	<hr/>
	-	7,864
	<hr/>	<hr/>

SCLERODERMA SOCIETY (THE)

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2016

13 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 April 2015	Movement in funds			Balance at 31 March 2016
		Income	Expenditure	Transfers	
	£	£	£	£	£
BAD	274	-	(274)	-	-
The Marjory Ingram Legacy	73,768	-	(73,768)	-	-
Medical equipment appeal	100	35	(135)	-	-
Research	245	160	(405)	-	-
Brian Norris Appeal	-	25,929	(15,383)	(10,546)	-
Actelion	-	1,500	(1,500)	-	-
FESCA	-	10,052	(10,052)	-	-
	74,387	37,676	(101,517)	(10,546)	-

The British Association of Dermatologists ("BAD") grant was to help towards the production of a series of on-line patient information videos.

Under the terms of the legacy bequeathed by Marjorie Ingram, the amounts received are to be used for medical research.

On 1 November 2015, the restricted funds were transferred to Scleroderma & Raynaud's UK.

14 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 April 2015	Movement in funds			Balance at 31 March 2016
		Income	Expenditure	Transfers	
	£	£	£	£	£
Development fund	160,000	-	(33,370)	(126,630)	-
	160,000	-	(33,370)	(126,630)	-

The development fund comprises unrestricted funds which the trustees have designated for the development and growth of the organisation. The balance of the fund was transferred to unrestricted fund further to the merger disclosed in note 15.

SCLERODERMA SOCIETY (THE)

NOTES TO THE ACCOUNTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2016

15 Related parties

On 7 October 2015, a deed of transfer was signed between The Scleroderma Society and Scleroderma & Raynaud's UK, a registered charity in which The Society transferred all its assets and liabilities to SRUK with effect from 1 November 2015. The Trustees of the Society joined the SRUK Trustee board on the same day.

On 1 November 2015, the total assets transferred was £478,594 including bank balance of £460,920 and total liabilities transferred of £18,890. SRUK is currently in the process of opening the bank account. As a result of this, The Society is holding the cash on behalf of SRUK as at the year end.